Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient

Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy

(2017) T. Schwarzberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial

(2017) S. Hariharan et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

(2017) R. A. Figlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma

(2008) B. Melichar et al.   ANNALS OF ONCOLOGY

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

(2008) Jacob A. Klapper et al.   CANCER

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

(2008) M. L. Nickerson et al.   CLINICAL CANCER RESEARCH

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

(2008) Guru Sonpavde et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

mTOR pathway in renal cell carcinoma

(2008) Sara C Hanna et al.   Expert Review of Anticancer Therapy

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial

(2008) David Cella et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma

(2008) Vitaly Margulis et al.   JOURNAL OF UROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

(2007) I. Tamaskar et al.   ANNALS OF ONCOLOGY

Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

(2007) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of Sunitinib or Sorafenib in Patients With Metastatic Renal Cell Carcinoma Who Received Prior Antiangiogenic Therapy

(2007) Ila Tamaskar et al.   JOURNAL OF UROLOGY